GREAT-SUN(SH:603336) Shang Hai Zheng Quan Bao·2025-09-22 18:48Core Viewpoint - The company will continue to focus on its core business of fruits and vegetables despite the change in its actual controller, who has a background in pharmaceuticals [3][4]. Group 1: Event Overview - The company participated in the "2025 Guangdong Listed Companies Investor Online Reception Day" and held a half-year performance briefing on September 19, 2025 [1]. - The event was conducted through the "Panorama Roadshow" website, allowing for interactive communication with investors [1]. Group 2: Key Questions and Responses - The company confirmed that it will maintain its focus on the fruits and vegetables business, emphasizing its experience and market share in this sector [3]. - There are currently no plans for collaboration with Teng Rui Pharmaceutical, and any future cooperation will be disclosed in accordance with legal requirements [3][4]. - The company is open to strategic development opportunities, including potential mergers or asset injections, but will adhere to strict evaluation and disclosure processes [4][5]. - The establishment of Shanghai Juhui Ze Pharmaceutical Technology Co., Ltd. is seen as an initial attempt to optimize business layout and enhance competitiveness, not a shift to a pharmaceutical focus [4]. - The company has prepared marketing strategies for the upcoming Mid-Autumn Festival and National Day, including the promotion of its "Fengshou Ge" brand products [4]. - Future growth will be driven by maintaining focus on core business, innovation, and improving operational quality and profitability [5]. - The company has outlined a three-year shareholder return plan (2025-2027) to ensure cash dividends and protect minority investors' rights [5].